Galapagos Restructures, Splits into Two, Cuts 300 Jobs
Galapagos, a Dutch-Belgian biotech firm facing financial struggles after setbacks in US market approvals, is splitting into two entities: one focusing on oncology cell therapy, and SpinCo, receiving \u20ac2.45 billion for acquisitions, resulting in 300 job cuts and separation from a restrictive agre...
Galapagos Restructures, Splits into Two, Cuts 300 Jobs
Galapagos, a Dutch-Belgian biotech firm facing financial struggles after setbacks in US market approvals, is splitting into two entities: one focusing on oncology cell therapy, and SpinCo, receiving \u20ac2.45 billion for acquisitions, resulting in 300 job cuts and separation from a restrictive agre...
Progress
40% Bias Score
Defeated PBM Reform Bill Fails to Address Core Issues
The FTC's July 2024 report criticized PBM practices, leading to a lawsuit; a defeated bill (HR II Section 227) attempted reform but failed to address core issues like rebates and transparency, potentially increasing costs and administrative burden.
Defeated PBM Reform Bill Fails to Address Core Issues
The FTC's July 2024 report criticized PBM practices, leading to a lawsuit; a defeated bill (HR II Section 227) attempted reform but failed to address core issues like rebates and transparency, potentially increasing costs and administrative burden.
Progress
56% Bias Score
China Tightens Business Inspections, Reforms Pharmaceutical Regulations
The Chinese State Council approved a guideline to strictly regulate administrative inspections of businesses and reform drug and medical device regulations to promote high-quality development of the pharmaceutical industry, addressing arbitrary actions affecting business operations and market expect...
China Tightens Business Inspections, Reforms Pharmaceutical Regulations
The Chinese State Council approved a guideline to strictly regulate administrative inspections of businesses and reform drug and medical device regulations to promote high-quality development of the pharmaceutical industry, addressing arbitrary actions affecting business operations and market expect...
Progress
36% Bias Score
Congress Fails to Pass PBM Reform
Congress failed to pass legislation reforming pharmacy benefit managers (PBMs), despite bipartisan efforts, leaving in place an industry criticized for opaque practices and potential conflicts of interest. The legislation aimed to increase transparency and change the compensation structure of PBMs, ...
Congress Fails to Pass PBM Reform
Congress failed to pass legislation reforming pharmacy benefit managers (PBMs), despite bipartisan efforts, leaving in place an industry criticized for opaque practices and potential conflicts of interest. The legislation aimed to increase transparency and change the compensation structure of PBMs, ...
Progress
40% Bias Score
Pfizer's 2025 Forecast Meets Expectations Amidst Medicare Changes and Investor Scrutiny
Pfizer projects 2025 profits near analyst estimates, anticipating stable Covid-19 product sales despite a \$1 billion revenue reduction from Medicare changes and ongoing investor pressure following a 12% share decline this year.
Pfizer's 2025 Forecast Meets Expectations Amidst Medicare Changes and Investor Scrutiny
Pfizer projects 2025 profits near analyst estimates, anticipating stable Covid-19 product sales despite a \$1 billion revenue reduction from Medicare changes and ongoing investor pressure following a 12% share decline this year.
Progress
36% Bias Score
Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Amidst Reduced COVID-19 Vaccine Sales
Pfizer's Dutch subsidiary reported an $11.4 billion profit for the fiscal year ending November 2023, down from previous years due to reduced COVID-19 vaccine and medication sales, but comparable to pre-pandemic levels; the company's revenue decreased from $74.4 billion in 2022 to $46.9 billion in 20...
Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Amidst Reduced COVID-19 Vaccine Sales
Pfizer's Dutch subsidiary reported an $11.4 billion profit for the fiscal year ending November 2023, down from previous years due to reduced COVID-19 vaccine and medication sales, but comparable to pre-pandemic levels; the company's revenue decreased from $74.4 billion in 2022 to $46.9 billion in 20...
Progress
40% Bias Score
China's Plan to Reform Pharmaceutical Industry and Become Global Powerhouse by 2035
China issued a guideline to reform drug and medical device regulations, aiming to become a global pharmaceutical leader by 2035, involving 24 measures across five key areas to improve innovation, review efficiency, supervision, opening up and regulatory systems; by 2027, it aims to enhance legal fra...
China's Plan to Reform Pharmaceutical Industry and Become Global Powerhouse by 2035
China issued a guideline to reform drug and medical device regulations, aiming to become a global pharmaceutical leader by 2035, involving 24 measures across five key areas to improve innovation, review efficiency, supervision, opening up and regulatory systems; by 2027, it aims to enhance legal fra...
Progress
32% Bias Score
Novo Nordisk Stock Plummets 40% on CagriSema Trial Results
Novo Nordisk's stock price has fallen 40% from its June high due to market correction following less-than-expected phase III trial results for its new obesity drug, CagriSema (20.4% weight reduction vs. projected 25%), which impacted investor confidence in its future growth projections and added to ...
Novo Nordisk Stock Plummets 40% on CagriSema Trial Results
Novo Nordisk's stock price has fallen 40% from its June high due to market correction following less-than-expected phase III trial results for its new obesity drug, CagriSema (20.4% weight reduction vs. projected 25%), which impacted investor confidence in its future growth projections and added to ...
Progress
40% Bias Score
Eli Lilly Stock Soars on Obesity Drug Success
Eli Lilly's stock has risen 33.7% this year due to the success of its obesity drug Mounjaro, projected to generate \$5.1 billion in sales, exceeding initial forecasts by \$3.2 billion; the company is investing in manufacturing to meet demand and is awaiting FDA approval for expanded uses of its drug...
Eli Lilly Stock Soars on Obesity Drug Success
Eli Lilly's stock has risen 33.7% this year due to the success of its obesity drug Mounjaro, projected to generate \$5.1 billion in sales, exceeding initial forecasts by \$3.2 billion; the company is investing in manufacturing to meet demand and is awaiting FDA approval for expanded uses of its drug...
Progress
48% Bias Score
Rovi Expands Audit Reports Following CNMV Requirements on Sustainability
Following a CNMV request, Laboratorios Rovi expanded its audit reports to address climate change mitigation, ESG objectives, alternative performance measures, ethical channels, and water usage in its Alcalá de Henares and San Sebastián de los Reyes plants, with plans to update the ESG plan in 2025.
Rovi Expands Audit Reports Following CNMV Requirements on Sustainability
Following a CNMV request, Laboratorios Rovi expanded its audit reports to address climate change mitigation, ESG objectives, alternative performance measures, ethical channels, and water usage in its Alcalá de Henares and San Sebastián de los Reyes plants, with plans to update the ESG plan in 2025.
Progress
32% Bias Score
McKinsey to Pay $650 Million in Opioid Settlement
McKinsey & Company agreed to pay $650 million to settle federal charges for its role in boosting OxyContin sales, including $2 million to Virginia's Medicaid Fraud Control Unit; a former partner pleaded guilty to obstruction of justice.
McKinsey to Pay $650 Million in Opioid Settlement
McKinsey & Company agreed to pay $650 million to settle federal charges for its role in boosting OxyContin sales, including $2 million to Virginia's Medicaid Fraud Control Unit; a former partner pleaded guilty to obstruction of justice.
Progress
52% Bias Score
Eli Lilly Stock Rebounds After Initial Post-Election Dip
Post-election, Eli Lilly's stock initially fell 6% due to concerns over President-elect Trump's choice for Health and Human Services, but has since rebounded due to meetings between Eli Lilly's CEO and the President-elect, coupled with Elon Musk's public support for affordable weight-loss drugs, ind...
Eli Lilly Stock Rebounds After Initial Post-Election Dip
Post-election, Eli Lilly's stock initially fell 6% due to concerns over President-elect Trump's choice for Health and Human Services, but has since rebounded due to meetings between Eli Lilly's CEO and the President-elect, coupled with Elon Musk's public support for affordable weight-loss drugs, ind...
Progress
44% Bias Score